Royalty Pharma (RPRX) reported 736millioninrevenueforthequarterendedDecember2023,representingayear−over−yeardeclineof30.81.15 for the same period compares to 1.56ayearago.Thereportedrevenuerepresentsasurpriseof+4.71702.9 million. With the consensus EPS estimate being $1.03, the EPS surprise was +11.65%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...